AI models using quantum computing will be tested on live currency data

UWM Holdings and UWM Acquisitions 1 LLC sued Two Harbors Investment Corp. in federal court, seeking more than $500 million in damages, alleging breach of contract and fraud tied to the collapse of a $1.3 billion merger. UWM reported a $603.2 million derivatives loss and $451.9 million Q2 net loss after a hedge built for the deal. Two Harbors accepted CrossCountry’s $12 cash offer; CrossCountry agreed to a $25.4 million termination fee.

Meta (META) partners with Shopify (SHOP) to expand Muse AI's commerce capabilities, enabling agentic checkout and product discovery. This follows Amazon's block on Muse, highlighting Meta's push for AI-driven transactions beyond advertising.

Alibaba (BABA) unveiled the Zhenwu V900 AI chip, claiming 3x performance improvement over its predecessor. The chip is set for mass production, with commercial availability expected in Q1 2025. Alibaba has invested $53 billion in AI and cloud infrastructure over three years, aiming to expand its cloud data center capacity to 20 gigawatts by 2032.

North Gyeongsang Province, Gumi City, IonQ, and SDT signed a deal to build a 75 billion won quantum system foundry. SDT will produce parts for IonQ's quantum computers, connecting to global supply chains. IonQ, listed on the NYSE, aims to expand manufacturing capabilities. The project addresses Korea's lack of quantum parts production and is part of a broader regional strategy.

Merck and Moderna reported positive Phase 3 trial results for their personalized mRNA vaccine, intismeran autogene (mRNA-4157), combined with pembrolizumab, showing longer recurrence-free survival in high-risk melanoma patients. The vaccine is tailored to each patient's tumor mutations. Detailed data and regulatory review are pending. Accessibility in regions like India may be challenging due to high costs and infrastructure needs.

Moderna has started a Phase 1 trial in Canada for its mRNA-1469 vaccine candidate targeting the Bundibugyo strain of Ebola. The trial, supported by CEPI, will enroll 80 people to assess safety and immune response, not efficacy. No results are available yet. This is one of two Bundibugyo-specific vaccine candidates in human testing, with the other developed by the University of Oxford and the Serum Institute of India.